TSFECG04:	Shift From Baseline to Maximum On-treatment Corrected QT Interval; Safety Analysis Set (Study jjcs - core)							
QTc Interval 	 	 	 	 	 	 	
  Treatment Group 	 	Baseline Corrected QT Interval 	Baseline Corrected QT Interval 	Baseline Corrected QT Interval 	Baseline Corrected QT Interval 	Baseline Corrected QT Interval 	
    Criteria, n 	N 	≤450 	>450 to ≤480  	>480 to ≤500 	>500 	Total 	
Xanomeline High Dose 	53 	 	 	 	 	 	
Xanomeline Low Dose 	73 	 	 	 	 	 	
Placebo 	59 	 	 	 	 	 	
 	  	  	  	  	  	  	
QTcB Interval, Aggregate (msec) 	 	 	 	 	 	 	
Xanomeline High Dose 	53 	 	 	 	 	 	
Maximum Corrected QT Interval 	 	 	 	 	 	 	
≤450 	 	31 	2 	3 	5 	41 	
>450 to ≤480  	 	4 	0 	2 	0 	6 	
>480 to ≤500 	 	1 	0 	0 	1 	2 	
>500 	 	1 	2 	0 	1 	4 	
Total 	 	37 	4 	5 	7 	53 	
 	 	 	 	 	 	 	
Xanomeline Low Dose 	53 	 	 	 	 	 	
Maximum Corrected QT Interval 	 	 	 	 	 	 	
≤450 	 	31 	3 	2 	2 	38 	
>450 to ≤480  	 	2 	1 	0 	1 	4 	
>480 to ≤500 	 	4 	1 	0 	1 	6 	
>500 	 	5 	0 	0 	0 	5 	
Total 	 	42 	5 	2 	4 	53 	
 	 	 	 	 	 	 	
Placebo 	56 	 	 	 	 	 	
Maximum Corrected QT Interval 	 	 	 	 	 	 	
≤450 	 	40 	4 	1 	2 	47 	
>450 to ≤480  	 	2 	0 	1 	1 	4 	
>480 to ≤500 	 	2 	0 	0 	0 	2 	
>500 	 	0 	0 	2 	1 	3 	
Total 	 	44 	4 	4 	4 	56 	
 	 	 	 	 	 	 	
QTcF Interval, Aggregate (msec) 	 	 	 	 	 	 	
Xanomeline High Dose 	53 	 	 	 	 	 	
Maximum Corrected QT Interval 	 	 	 	 	 	 	
≤450 	 	33 	2 	4 	3 	42 	
>450 to ≤480  	 	3 	0 	0 	0 	3 	
>480 to ≤500 	 	6 	0 	0 	0 	6 	
>500 	 	2 	0 	0 	0 	2 	
Total 	 	44 	2 	4 	3 	53 	
 	 	 	 	 	 	 	
Xanomeline Low Dose 	53 	 	 	 	 	 	
Maximum Corrected QT Interval 	 	 	 	 	 	 	
≤450 	 	34 	2 	0 	4 	40 	
>450 to ≤480  	 	3 	0 	0 	1 	4 	
>480 to ≤500 	 	4 	0 	0 	0 	4 	
>500 	 	4 	0 	1 	0 	5 	
Total 	 	45 	2 	1 	5 	53 	
 	 	 	 	 	 	 	
Placebo 	56 	 	 	 	 	 	
Maximum Corrected QT Interval 	 	 	 	 	 	 	
≤450 	 	29 	6 	5 	3 	43 	
>450 to ≤480  	 	2 	0 	0 	0 	2 	
>480 to ≤500 	 	4 	1 	0 	0 	5 	
>500 	 	5 	1 	0 	0 	6 	
Total 	 	40 	8 	5 	3 	56 	

Note: On-treatment is defined as QTc interval values obtained after the first dose and within [30 days] following treatment discontinuation. 	
Note: On-treatment is defined as QTc interval values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as QTc interval values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as QTc interval values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as QTc interval values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as QTc interval values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: On-treatment is defined as QTc interval values obtained after the first dose and within [30 days] following treatment discontinuation.	
Note: N is the number of subjects with non-missing values for the ECG parameter at baseline and at least 1 postbaseline visit. 	: N is the number of subjects with non-missing values for the ECG parameter at baseline and at least 1 postbaseline visit.	: N is the number of subjects with non-missing values for the ECG parameter at baseline and at least 1 postbaseline visit.	: N is the number of subjects with non-missing values for the ECG parameter at baseline and at least 1 postbaseline visit.	: N is the number of subjects with non-missing values for the ECG parameter at baseline and at least 1 postbaseline visit.	: N is the number of subjects with non-missing values for the ECG parameter at baseline and at least 1 postbaseline visit.	: N is the number of subjects with non-missing values for the ECG parameter at baseline and at least 1 postbaseline visit.